Prognostic factors of patients with yolk sac tumors of the ovary

Nawa, Akihiro; Obata, Nobuaki; Kikkawa, Fumitaka; Kawai, Michiyasu; Nagasaka, Tetsuo; Goto, Setsuko; Nishimori, Katsuhiko; Nakashima, Naoki

doi:10.1067/mob.2001.113323

Cited by 120 publications

(131 citation statements)

References 19 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Previous analyses from Japan were mostly from the pre-BEP era (Kawai et al 1991;Fujita et al 1993;Nawa et al 2001), and one study reported on 10 BEP-treated patients (Umezu et al 2008).…”

Section: Discussionmentioning

confidence: 99%

“…To date, the reported prognostic factors of YST are as follows: stage (Kawai et al 1991;de La Motte Rouge et al 2011), residual tumor (Kawai et al 1991;Nawa et al 2001;Umezu et al 2008;Cicin et al 2009), ascites (Kawai et al 1991;Nawa et al 2001;Umezu et al 2008;de La Motte Rouge et al 2011), cisplatin-containing chemotherapy in advanced cases (Kawai et al 1991), BEP therapy (Cicin et al 2009;de La Motte Rouge et al 2011), AFP half-life (de La Motte Rouge et al 2011, and time to serum AFP normalization (de La Motte Rouge et al 2011). In our data, univariate analysis revealed that the candidate prognostic factors were stage (P = 0.046), tumor diameter (P = 0.015), and residual tumor diameter (P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin-containing chemotherapy is one of the prognostic factors (Kawai et al 1991;Nawa et al 2001). Among cisplatin-including regimens, BEP is more effective than others (Cicin et al 2009).…”

Section: Discussionmentioning

confidence: 99%

“…In Japan, there have been three studies of YST that included 29, 41, and 47 patients, respectively (Kawai et al 1991;Fujita et al 1993;Nawa et al 2001), in which non-BEP regimen as adjuvant chemotherapy was given. In addition, Umezu et al (2008) analyzed 36 patients with YST, among whom10 patients (28%) were treated with BEP.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Yolk Sac Tumor of the Ovary: A Retrospective Multicenter Study of 33 Japanese Women by Tohoku Gynecologic Cancer Unit (TGCU)

Kojimahara

Nakahara

Takano

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Yolk sac tumor (YST) of the ovary is a rare germ cell tumor comprising about 1% of all ovarian malignancies. YST usually occurs as a rapidly growing unilateral tumor in young women. With the introduction of cisplatin, YST has been changed from a fatal tumor to a curable tumor. The standard treatment of YST consists of fertility-preserving surgery and 3 or 4 courses of adjuvant combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP). However, the long-term prognosis of BEP-treated YST patients has not been well studied. We therefore conducted a retrospective multicenter study to investigate the prognostic factors of 33 YST patients, including 25 patients treated with BEP. The median age at initial treatment was 20 years (range 10-53). There were 15 patients (at stage I), one (stage II), 16 (stage III), and one (stage IV). Nominal and grouped numerical values were analyzed by the KaplanMeier method. All patients had unilateral tumor, with right-side predominance (23 patients; P = 0.02). Eighteen patients had pure YST, 13 had mixed germ cell tumor with YST component, and other 2 patients were not specified. Twenty-eight patients received fertility-preserving surgery. Twenty-seven patients had optimal surgery with less than 1 cm residual tumor diameter. Median number of chemotherapy courses was 5. Median follow-up period was 49 months. The cumulative 5-year survival rate was 87%. Univariate analysis revealed the following significant prognostic factors (P < 0.05): stage, tumor diameter, and residual tumor. Extensive debulking surgery to minimize residual tumor would improve the prognosis.

show abstract

“…Previous analyses from Japan were mostly from the pre-BEP era (Kawai et al 1991;Fujita et al 1993;Nawa et al 2001), and one study reported on 10 BEP-treated patients (Umezu et al 2008).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Yolk Sac Tumor of the Ovary: A Retrospective Multicenter Study of 33 Japanese Women by Tohoku Gynecologic Cancer Unit (TGCU)

Kojimahara

Nakahara

Takano

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Gradually, BEP results showed its efficacy in achieving long remission periods and fairly adequate drug tolerance. A review of 47 patients with fertility-sparing surgery and cisplatin regimen had good prognosis, documented by Japanese study in last two decades of twentieth century [10,11].…”

Section: An Overview Of Management Protocolsmentioning

confidence: 99%

Childhood Ovarian Malignancy

Mahadik

Ghorpade

2014

J Obstet Gynecol India

View full text Add to dashboard Cite

Objective of this article is to appraise diagnostic aspects and treatment modalities in childhood ovarian tumor in background of available evidence. Literature search on Pubmed revealed various aspects of epidemiology, histopathological diagnosis, and treatment of pediatric ovarian tumor. 85 % of childhood tumors are germ cell tumors. The varied histopathological picture in germ cell tumors poses a diagnostic and therapeutic challenge. Immunohistochemistry and newer genetic markers like SALL4 and karyopherin-2 (KPNA2) have been helpful in differentiating ovarian yolk sac tumor from dysgerminoma, teratomas, and other pictures of hepatoid, endometrioid, clear cell carcinomatous, and adenocarcinomatous tissues with varied malignant potential. Before platinum therapy, these tumors were almost fatal in children. Fertility-conserving surgery with bleomycin, etoposide, and cisplatin has dramatically changed the survival rates in these patients. This modality gives cancer cure with healthy offspring to female patients with childhood ovarian tumor. Evidence also supports this protocol resulting in successful pregnancy rates and safety of cytotoxic drugs in children born to these patients.

show abstract